These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12831811)

  • 1. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy.
    Vassalli G; Gallino A; Weis M; von Scheidt W; Kappenberger L; von Segesser LK; Goy JJ;
    Eur Heart J; 2003 Jul; 24(13):1180-8. PubMed ID: 12831811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium.
    Hosenpud JD; Everett JP; Morris TE; Mauck KA; Shipley GD; Wagner CR
    Circulation; 1995 Jul; 92(2):205-11. PubMed ID: 7600652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and prophylaxis of cardiac allograft vasculopathy.
    Wang SS
    Transplant Proc; 2008 Oct; 40(8):2609-10. PubMed ID: 18929815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiogenic shock and coronary endothelial dysfunction predict cardiac allograft vasculopathy after heart transplantation.
    Lopez-Fernandez S; Manito-Lorite N; Gómez-Hospital JA; Roca J; Fontanillas C; Melgares-Moreno R; Azpitarte-Almagro J; Cequier-Fillat A
    Clin Transplant; 2014 Dec; 28(12):1393-401. PubMed ID: 25284267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathogenesis of cardiac allograft vasculopathy.
    Dong C; Redenbach D; Wood S; Battistini B; Wilson JE; McManus BM
    Curr Opin Cardiol; 1996 Mar; 11(2):183-90. PubMed ID: 8736690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac allograft vasculopathy--a changing perspective.
    Russell ME
    Z Kardiol; 2000; 89 Suppl 9():IX/6-10. PubMed ID: 11151796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac allograft vasculopathy.
    Behrendt D; Ganz P; Fang JC
    Curr Opin Cardiol; 2000 Nov; 15(6):422-9. PubMed ID: 11198625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication management of cardiac allograft vasculopathy after heart transplantation.
    Hollis IB; Reed BN; Moranville MP
    Pharmacotherapy; 2015 May; 35(5):489-501. PubMed ID: 26011142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplant vasculopathy.
    Deng MC; Tjan TD; Asfour B; Roeder N; Scheld HH
    Herz; 1998 May; 23(3):197-201. PubMed ID: 9646102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cardiac allograft vasculopathy - A new possible indication for SGLT-2 inhibitors?
    Grubić Rotkvić P; Cigrovski Berković M; Rotkvić L; Bulj N
    Med Hypotheses; 2020 Apr; 137():109594. PubMed ID: 32006921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal.
    Mehra MR; Ventura HO; Chambers RB; Ramireddy K; Smart FW; Stapleton DD
    J Heart Lung Transplant; 1997 Jul; 16(7):743-51. PubMed ID: 9257256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility.
    Costanzo-Nordin MR
    J Heart Lung Transplant; 1992; 11(3 Pt 2):S90-103. PubMed ID: 1623009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway.
    Weis M; Cooke JP
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):567-75. PubMed ID: 12649081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do calcium channel blockers and HMG-CoA reductase inhibitors attenuate allograft arteriopathy?
    Valantine-von Kaeppler HA
    Curr Opin Cardiol; 1998 Mar; 13(2):111-6. PubMed ID: 9593550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children.
    Hussain T; Burch M; Fenton MJ; Whitmore PM; Rees P; Elliott M; Aurora P
    Circulation; 2007 Apr; 115(13):1798-805. PubMed ID: 17353448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental cardiac allograft vasculopathy in mice.
    Ardehali A; Billingsley A; Laks H; Drinkwater DC; Sorensen TJ; Drake TA
    J Heart Lung Transplant; 1993; 12(5):730-5. PubMed ID: 8241210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy.
    Lee RS; Yamada K; Houser SL; Womer KL; Maloney ME; Rose HS; Sayegh MH; Madsen JC
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3276-81. PubMed ID: 11248069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and humoral immunity to vascular endothelium and the development of cardiac allograft vasculopathy.
    Hosenpud JD; Everett JP; Morris TE; Wagner CR; Shipley GD
    J Heart Lung Transplant; 1995; 14(6 Pt 2):S185-7. PubMed ID: 8719483
    [No Abstract]   [Full Text] [Related]  

  • 20. [Coronary allograft vasculopathy: pathophysiological interaction between the immune system, infections and metabolic syndrome].
    Potena L; Ferrara R; Mocarski ES; Lewis DB; Cooke JP; Grigioni F; Coccolo F; Magnani G; Fallani F; Magelli C; Valantine HA; Branzi A
    G Ital Cardiol (Rome); 2007 Feb; 8(2):73-82. PubMed ID: 17402351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.